Articles tagged with Drug Discovery
Researchers at University of Minnesota and Dow Chemical Company developed a new method for customizing ingredients in oral medications to improve solubility and absorption. The discovery has the potential to lower production costs and advance the development of life-saving drugs.
Researchers at Johns Hopkins Medicine have developed a modified cancer drug that enhances its ability to reach the brain, improving delivery and reducing toxicity. The new compound shows promise in treating brain tumors by targeting tumor metabolism and evading immune cells.
Researchers explore using human pluripotent stem cells to identify cardiotoxicity risks in patients taking chemotherapy agents and other drugs. This approach may boost the number of successful clinical trials for cardiovascular disease treatments.
The article presents a comprehensive overview of in silico drug repurposing methods, highlighting the advantages and disadvantages of various techniques. The authors emphasize the potential of incorporating deep learning approaches into modular workflows, which can accelerate development and reduce costs.
The team created highly uniform arrays of low surface tension functional water-based droplets for biochemical experiments, overcoming current patterning limitations. This non-contact method has potential applications in drug discovery and clinical diagnostics.
Insilico Medicine will present new research data on geroprotectors, small molecules that mimic the young healthy state in old human tissues. The results are a result of a multi-year research program with multiple in silico predictions made using algorithms validated using data from many age-related diseases.
Researchers at the University of Georgia have discovered a new drug that can be administered orally to treat human African trypanosomiasis, a parasitic disease affecting rural communities in sub-Saharan Africa. The study's lead author hopes to accelerate development of new treatments for this complex disease.
Researchers at UNIST have developed a new synthetic method to design and synthesize bioactive compounds and chemical tools for pharmacological studies. This breakthrough improves the scientific basis for drug discovery by understanding biochemical mechanisms for diseases.
A global team of researchers has created and tested a panel of 400 chemical compounds, dubbed the 'Malaria Box', with potential application as therapeutic starting points for diseases like malaria, trypanosomiasis and toxoplasmosis. The collaboration opens new doors for international advances in drug discovery.
Researchers at University of Leeds and Hebei Medical University found that Substance P reduces sensations of pain in peripheral nervous system but triggers pain in central nervous system. This discovery could lead to new methods for pain control with limited side effects.
Researchers from around the world collaborated on an open-source drug-discovery project, identifying compounds to treat malaria, other parasites, and even cancer. The successful trial has sparked over a dozen new drug-development projects, bridging the gap between academia and industry.
Scientists at the University of Sussex are developing new cancer drugs that target DNA damage response pathways to selectively kill cancer cells. These drugs aim to maximize DNA damage or prevent its repair, leading to cancer cell death while minimizing harm to healthy tissues.
Researchers at Thomas Jefferson University have found a new way to keep the heart pumping, which could lead to new drugs for heart disease. By activating the beta2-adrenergic receptor, they can promote the contraction of heart muscle cells and potentially treat heart failure.
Seattle researchers deciphered how tuberculosis bacteria tolerates bedaquiline by silencing regulatory genes or pairing with pretomanid, disrupting tolerance gene networks to improve efficacy. This systems-approach represents a significant advance in the fight against tuberculosis.
Insilico Medicine scientists will present advances in deep learning for biomarker development and drug discovery at the ISFA-Columbia University Actuarial Science Workshop. The workshop aims to integrate deep learning with actuarial science to assess risk in finance, insurance, and other industries.
Fifty NSF-funded biotech companies will exhibit innovative products and processes, including diagnostics and monitoring technologies, drug discovery platforms, and engineering biology innovations. These early-stage companies have the potential to transform the US healthcare system with novel high-tech solutions.
Scientists from Insilico Medicine used deep neural networks to predict therapeutic use of large numbers of drugs from gene expression data, achieving 54.6% accuracy in class prediction. The study also found that many misclassified drugs had dual use, suggesting potential for drug repurposing.
Insilico Medicine presents research on applying deep learning to biomarker development and cosmetics applications at INNOCOS World Beauty Innovation Summit. The company's app RYNKL evaluates anti-aging interventions using machine learning methods, minimizing animal testing.
Researchers have identified a chemical compound eCF506 that effectively blocks breast cancer cell growth, targeting a specific molecule required for tumor progression. The findings suggest eCF506 may be more effective and have fewer side effects than existing drugs, with further studies needed to confirm its potential.
A new database has been developed to connect environmental exposures to human health effects and compare diseases. The Comparative Toxicogenomics Database (CTD) manually curates data from scientific literature on how environmental chemicals interact with genes to affect human health.
A promising discovery has been made in treating and preventing human parainfluenza virus, the second most prevalent cause of acute respiratory tract infection in infants. Researchers have found that combining two existing drugs, Suramin and Relenza, can effectively block the infection.
A team of scientists has identified a possible use for the leukemia treatment drug Imatinib in treating type 2 diabetes. Gleevec was found to lower insulin resistance by controlling PPARγ, reducing the risk of hyperglycemia and obesity.
Saint Louis University researcher Fran Sverdrup is developing a treatment for Facioscapulohumeral Muscular Dystrophy (FSHD), a disease that causes muscle degeneration in 15,000 or more people. Ultragenyx will fund the process of turning SLU's initial discoveries into a drug that could demonstrate proof of concept.
Researchers at U of T Engineering have developed a new way of growing realistic human tissues outside the body, called AngioChip. The technology uses a three-dimensional structure complete with internal blood vessels and can be used to test drugs on lab-grown human tissues, providing a realistic model at a fraction of the cost.
Experts argue that drug discovery should focus on 'validity', predicting results in sick people, rather than industrialization or fashion. Mathematical tools show that small changes in validity can have a bigger effect than running more experiments.
A study published in The Lancet Neurology found that people with Parkinson's who took the oral drug rivastigmine were 45% less likely to fall and steadier when walking. This breakthrough treatment has the potential to improve quality of life for millions worldwide.
InSilico Medicine presents recent advances in applying signaling pathway activation analysis and deep learning to drug discovery and age-related diseases. The company's mission is to extend healthy human longevity through faster and more effective diagnostics and cures.
Researchers have developed a computer model that applies social network analysis techniques to identify new ways of treating cancer. The model maps the interactions between cancer-causing proteins, predicting which ones will be most effectively targeted with drugs.
The Deep Knowledge Life Sciences (DKLS) investment fund will invest in companies with breakthrough technologies, focusing on genetics of age-related diseases, oncology, and regenerative medicine. DKLS will combine AI insights from VITAL with top-level expertise to create analyses and treatments for diseases while de-risking investments.
Researchers at Griffith University have made a groundbreaking discovery about how bacteria interact with human cells, revealing high-affinity biomolecular interactions between glycans that were previously thought to be weak or non-existent. This finding opens up new avenues for developing vaccines and drugs to block infections.
A team of researchers at UCSF developed ORACLs, a lineage of genetically modified cancer cells that change their appearance when treated with drugs, inspired by face-recognition software. These cells can quickly organize molecules in institutional compound libraries according to their biological function.
A team of researchers combined large genomic and proteomic datasets to identify new factors that can be targeted to prevent viruses from spreading. They found 20 previously unrecognized host proteins required for IAV replication, including the pivotal protein UBR4.
The Target Validation Platform provides a single, robust infrastructure that integrates high-level information from key sources of evidence. It enables communities to work together, making the hand-off from basic research to drug discovery smoother, and is expected to grow substantially as it integrates experimental project data.
Researchers at the University of York have developed a new approach to make medicinally important molecules with large rings, called macrocycles. This method allows for their 'growth' from existing rings using ring enlargement reactions, paving the way for the development of new classes of life-saving medicines.
The paper calls for creating a task force to evaluate the classification of aging as a disease in ICD-11. Classifying aging as a disease could help shift the focus from treatment to prevention, attracting more resources to aging research and business cases for pharmaceutical companies.
Scientists at UNC and UCSF create general tool to probe orphan receptor activity, illuminating their roles in behavior. They found a novel probe molecule that can modulate the orphan G protein-coupled receptor 68 (GPR68), which is highly expressed in the brain.
Scientists at UNC and UCSF developed a general tool to find homes for 'orphan' cell-surface receptors, illuminating their roles in behavior. The creation of the research tool allows researchers to learn how orphan receptors interact with molecules inside the body or with drugs.
Researchers have detected how nature produces key chemicals similar to those in drugs that fight malaria, bacterial infections and cancer. The discovery sheds light on a complicated chemical process in nature that synthetic biologists can now borrow to engineer a whole new class of synthetic medicines.
Scientists have made a breakthrough in understanding how the flu virus works by studying its M2 proton channel. Using advanced MRI technology, researchers gained insight into the virus's replication process, which could lead to the development of new prescription drugs.
A themed issue of Future Medicinal Chemistry highlights academia's role in drug discovery, discussing industry-academia alliances and novel models. The issue features expert commentaries on bridging the translational research gap and implementing open innovation platforms.
Researchers discovered that blocking TRPV1 protein causes an increased release of noradrenaline, leading to a rise in core body temperatures. This breakthrough opens the doors for new treatments of stress-related body temperature disorders.
Researchers at McGill University have developed a suite of computer programs to speed up the process of drug discovery for diseases like diabetes and Alzheimer's. The Fibrilizer program analyzes billions of possible genetic mutations to find weak spots in toxic protein strands, potentially leading to new treatments.
Researchers at Gladstone Institutes mapped the discovery path to two FDA-approved drugs, revealing that a large network of scientists contributed over decades. The study proposes new metrics to quantify the influence of individual scientists in accelerating future cures.
Researchers have found three new drug-like compounds that target a protein responsible for chemotherapy resistance in cancers, offering hope for improved treatment options. The compounds have shown promise in re-sensitizing resistant cancer cells to chemotherapy, improving the odds of survival for prostate cancer patients.
The Harrington Discovery Institute has selected scholars to collaborate with R&D partners, including University of Oxford, Alzheimer's Drug Discovery Foundation and Foundation Fighting Blindness. The program aims to bridge the 'Valley of Death' gap in bringing new medications from lab to market.
Researchers discovered that photoaging can be reversed by understanding how UV radiation affects skin fibers. Polina Mamoshina's study using Geroscope software platform analyzed pathway dysregulation in chronologically-aged and photoaged skin.
Researchers have successfully created functional liver cells from human embryonic and genetic engineered stem cells. The new method enables unlimited production of liver cells with high accuracy, revolutionizing pharmaceutical drug discovery and potentially improving treatment outcomes.
Scientists from InSilico Medicine have developed an approach to screen and rank geroprotective drugs using big data analysis, identifying compounds with potential geroprotective properties. The Geroscope software was applied to gene expression data derived from stem cells to select five drugs that displayed geroprotective action.
Researchers analyzed data from the Irish Longitudinal Study on Ageing and found a significant link between serious falls causing injury in older men taking certain medicines with potent anti-cholinergic effects. The risk was more than twice as likely in men compared to women.
Researchers at Kyoto University successfully visualized RNA behavior within living brain tissue of mice, enabling the study of RNA distribution and its response to drugs. This breakthrough technique holds promise for accelerating the discovery and development of new drugs.
Researchers at Concert Pharmaceuticals demonstrated selective deuterium substitution to improve safety, efficacy, tolerability and convenience of paroxetine-based medicines. Deuterated compounds retain potency but exhibit altered metabolic profiles, reducing drug-drug interactions.
A team of Vanderbilt chemists used a novel approach called 'fight clubs' to identify promising new anti-cancer compounds from natural sources. By analyzing the interactions between bacteria and other microorganisms, they discovered a class of biomolecules with broad-spectrum activity.
A new drug discovery project, funded by a £3m Dementia Consortium, aims to target brain inflammation in Alzheimer's disease. The project will explore novel therapeutics to dampen the inflammatory response, which is believed to contribute to the disease's damage.
Scientists have discovered new antifungal compounds that selectively kill pathogens without evoking drug resistance. These novel compounds were designed to act as molecular sponges for ergosterol, found exclusively on fungi surfaces, and exhibit undetectable binding to human cells.
The Wistar Institute has secured a $5.6 million grant renewal from the Wellcome Trust to further develop cancer drugs targeting Epstein-Barr virus (EBV). The goal is to create a therapeutic that can treat EBV-related cancers by attacking the virus as it remains dormant in patient cells.
A team of researchers has successfully engineered a yeast strain to produce morphine and potentially other drugs, including antibiotics and anti-cancer therapeutics. The breakthrough could significantly reduce the cost of drug discovery and manufacturing, but raises concerns about potential misuse and calls for urgent regulation.
Researchers at Cold Spring Harbor Laboratory have discovered the mechanism of action for BRD4, a protein critical to AML cell survival. Disrupting this pathway may lead to improved therapeutic strategies and new molecular targets for treating various cancers.
A research team from Griffith's Eskitis Institute led by Professor Vicky Avery receives a major boost to develop effective anti-malarial drugs against Plasmodium falciparum and Plasmodium vivax. The project aims to combat drug resistance and prevent relapse.
Researchers identified 422 structural clusters of naturally-derived fragments with diverse properties, suitable for chemical biology and drug discovery. These fragments could serve as the starting point for a highly diverse library with minimal structural complexity.
Scientists have discovered a molecular switch that allows human cytomegalovirus to enter dormancy or reactivate infection. By manipulating this switch with simple drugs, HCMV can be targeted with antivirals and purged from organs before transplantation.